Key Takeaways
- Independent pharmacies with 6+ months of dispensing revenue qualify for Bankable
- SBA pharmacy business loans unavailable to E-3 holders
- Drug inventory, working capital, and expansion all fundable
- PBM reimbursement cycles create AR float that Bankable bridges
- 48-hour decisions up to $3M
Australian pharmacists in the US on E-3 visas are credentialed professionals — the E-3 specialty occupation requirement ensures high qualification standards. Independent pharmacies operated by E-3 holders serve local communities with a level of personalised service that chain pharmacies don't provide. The business challenge is capital access: drug inventory must be purchased before dispensing, and PBM (pharmacy benefit manager) reimbursement typically arrives 15–30 days after dispensing.
Bankable funds independent pharmacies based on monthly dispensing revenue. No SBA, no green card, 48-hour decisions. We understand PBM reimbursement cycles, specialty pharmacy economics, and the working capital needs of pharmacy operations.
The E-3 Funding Barrier
The SBA's 100% citizen/national ownership rule disqualifies every E-3 holder from government-backed loans — regardless of how long you've been in the US, how profitable your business is, or how strong your credit score is. Banks that primarily originate SBA loans have no viable product to offer you. That's not a reflection of your business quality; it's a policy gap that Bankable was built to bridge.
Revenue-based funding through Bankable requires no green card, no citizenship, and no SBA involvement. What matters: your business generates consistent revenue, has been operating for at least 6 months, and has a US business bank account. That's the core of what we evaluate. Check your Bankability Score to see your options in minutes.
Challenges in This Sector
- Drug inventory must be purchased before dispensing and before PBM reimbursement
- PBM reimbursement takes 15–30 days creating significant AR float on high drug costs
- Specialty drugs have extremely high per-unit costs — $1K–$100K+ per prescription
- DIR fees (retroactive PBM adjustments) can significantly reduce expected revenue
- Pharmacy benefit management contracts require compliance investment
- Expanding into specialty pharmacy requires additional licensing and infrastructure
Funding Solutions for E-3 Holders
- Drug Inventory Financing: Working capital for drug purchasing before PBM reimbursement.
- AR Bridge: Cover PBM reimbursement timing (15–30 days after dispensing).
- Specialty Pharmacy Capital: Fund specialty drug inventory and infrastructure for high-cost medications.
- Expansion Capital: Open a second pharmacy location based on existing location revenue.
- Technology Investment: Pharmacy management system and dispensing technology upgrades.
Independent Pharmacy Revenue at Bankable
An independent pharmacy filling 200+ prescriptions per day at average reimbursement of $40 generates $8K/day or $240K+/month in dispensing revenue. After drug cost (COGS typically 70–80% of revenue), gross profit is $48K–$72K/month — a fundable base. Bankable evaluates net dispensing revenue (after drug costs) alongside gross revenue and bank deposits.
Capital Products Available
Revenue-Based Funding
Up to $5M based on your monthly revenue. No green card, no SBA. 48-hour decisions.
Apply Now →Equipment Financing
Asset-backed funding for equipment — available to non-citizen business owners.
Check Eligibility →Frequently Asked Questions
Yes. Pharmacy ownership laws vary by state but generally permit non-citizen pharmacist owners through pharmacy-specific entity structures.
Independent retail pharmacies, specialty pharmacies, compounding pharmacies, and long-term care pharmacies.
We bridge the 15–30 day PBM reimbursement cycle with working capital structured around your collection pattern.
Yes. High-cost specialty drug inventory working capital is a supported use case.
Typically $50K+/month in consistent dispensing revenue with positive net margins.
DIR fees are retroactive PBM adjustments that reduce effective reimbursement. We evaluate net revenue after DIR fee adjustments.
Yes. Expansion based on existing location performance is supported.
Yes. We understand PBM reimbursement, DIR fee structures, and drug cost economics.
48-hour decisions. Funds in 3–5 business days.
Yes. Pharmacy management systems and dispensing technology are valid capital investments.